A Review of Omalizumab for the Management of Severe Asthma

Drug Design, Development and Therapy - New Zealand
doi 10.2147/dddt.s112208
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Appropriate Selection for Omalizumab Treatment in Patients With Severe Asthma?

European Clinical Respiratory Journal
2017English

PRS44 Cost Utility Analysis of Omalizumab Therapy for Severe Asthma Patients in Thailand

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2011English

Omalizumab in Patients With Severe Asthma and Persistent Sputum Eosinophilia

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Lengthening Omalizumab Dosing Interval in Treatment of Moderate to Severe Persistent Asthma

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Omalizumab as Add‐on Therapy in a Patient With Severe Asthma and OSA

Respirology Case Reports
PulmonaryRespiratory Medicine
2020English

Omalizumab in the Treatment of Severe Allergic (IgE-mediated) Asthma: An Update on Recent Developments

Clinical and Translational Allergy
ImmunologyPulmonaryAllergyRespiratory Medicine
2013English

Omalizumab and Mepolizumab in the Landscape of Biological Therapy for Severe Asthma in Children: How to Choose?

Italian Journal of Pediatrics
Child HealthPediatricsPerinatology
2019English

Real-Life Effectiveness of Omalizumab in Severe Allergic Asthma Above the Recommended Dosing Range Criteria

Pediatrics
Child HealthPediatricsPerinatology
2017English

Efficacy and Safety of Treatment With Biologicals (Benralizumab, Dupilumab, Mepolizumab, Omalizumab and Reslizumab) for Severe Eosinophilic Asthma

Allergy: European Journal of Allergy and Clinical Immunology
AllergyImmunology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy